Floridienne (FLOB) H1 2025 earnings summary

Executive summary

• Group turnover grew 6.3% year-over-year to EUR 337.4 million as of 30 June 2025, driven by Life Sciences and recent acquisitions.

• Net consolidated result fell to EUR -8.2 million from EUR 5.3 million year-over-year, mainly due to currency volatility and unrealised exchange losses.

• Life Sciences Division saw strong sales growth, especially from BIOTROP in Brazil, but profitability was impacted by North American competition.

• Food Division benefited from cold sauces exports, but ingredient cost inflation weighed on margins.

• Chemicals Division faced lower turnover and profitability due to metal price declines and Turkish lira volatility.

Financial highlights

• Turnover: EUR 337.4 million (+6.3% year-over-year).

• EBITDA: EUR 36.0 million (-9.1% year-over-year).

• Net consolidated result: EUR -8.2 million (vs. EUR 5.3 million year-over-year).

• Equity capital: EUR 606.9 million, down EUR 26.1 million since December 2024.

• Net financial debt: EUR 229.1 million (vs. EUR 209.5 million at end-2024).

• Liquid assets: EUR 90.5 million.

Outlook and guidance

• Life Sciences expected to post record turnover and profitability, led by BIOTROP.

• Food Division investing to expand cold sauces capacity and maintain margins.

• Chemicals Division to increase recycling capacity; Kimflor expected to remain resilient.

• Board expects 2025 results broadly in line with 2024, despite external pressures.